BioFrontier Partners

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

CellZome is a pharmaceutical company based in Heidelberg, Baden-Württemberg, that specializes in the discovery, development, and commercialization of kinase-targeted drugs aimed at treating inflammatory diseases. Founded in 2000, the company focuses on creating a pipeline of kinase inhibitors that act on inflammatory mediators, offering oral therapeutic options for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.

Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

AnGes MG, Inc. is a biopharmaceutical company dedicated to developing innovative drugs for patients with diseases that currently lack effective therapies. Established in December 1999 based on research from Osaka University, AnGes specializes in gene medicine, which represents a next-generation approach to treatment. The company has successfully commercialized "Naglazyme®," a drug for mucopolysaccharidosis VI, and is advancing its HGF Plasmid gene therapy for critical limb ischemia through its final stages of clinical development. Additionally, AnGes is working on an NF-κB decoy oligonucleotide, a nucleic acid medicine designed to address various inflammatory conditions, including atopic dermatitis and disc degeneration. With a focus on research and practical application, AnGes aims to meet the expectations of patients, families, and investors while striving to become a global leader in the gene medicine sector.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.